Art. -Nr.: HY-B0744

Eflornithine

(Synonyms: DFMO; MDL71782; RMI71782; α-difluoromethylornithine)

23 Cited Publications

Kundenbewertung

Based on 23 publication(s) in Google Scholar

Eflornithine is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase. Eflornithine is a medication for the treatment of African trypanosomiasis and excessive facial hair growth in women.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.87%
CAS. Nr.: 70052-12-9
Formel: C₆H₁₂F₂N₂O₂
Molecular Weight:182.17

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Eflornithine Chemical Structure

CAS. Nr.: 70052-12-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vivo
- Clinical Trial
Chemical Information
Publications (23)
Lösungsmittel & Löslichkeit
- In Vitro
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Trypanosoma

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	EC₅₀	>100 μM Compound: Eflornithine	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay	[PMID: 27720295]
HepG2	CC₅₀	>100 μM Compound: Eflornithine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32292551]
HepG2	CC₅₀	>100 μM Compound: Eflornithine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32652409]
HepG2	CC₅₀	>100 μM Compound: Eflornithine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32795774]
L6	IC₅₀	12 μg/mL Compound: Eflornithine	Cytotoxicity against in rat L6 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay Cytotoxicity against in rat L6 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay	[PMID: 21353728]
MRC5	IC₅₀	>100 μg/mL Compound: eflornithine	Cytotoxicity against human MRC5 cells after 7 days by MTT assay Cytotoxicity against human MRC5 cells after 7 days by MTT assay	[PMID: 19013823]
MRC5	IC₅₀	>100 μg/mL Compound: Eflornithine	Cytotoxicity against human MRC5 cells Cytotoxicity against human MRC5 cells	[PMID: 24388808]

In Vivo

Eflornithine is the only new molecule registered for the treatment of human African trypanosomiasis over the last 50 years. It is the drug used mainly as a back-up for melarsoprol refractory Trypanosoma brucei gambiense cases^[1]. In subjects with excessive, unwanted facial hair, eflornithine 15% cream is superior to placebo in reducing hair growth. After 24 weeks' treatment, 58% of eflornithine and 34% of placebo subjects have at least some improvement in facial hirsutism^[2]. The hair growth inhibitory activity of eflornithine is significantly enhanced when the eflornithine cream is applied onto a mouse skin area pretreated with microneedles^[3]. Treatment of coarctation hypertensive rats with eflornithine results in a normalization of the contractile intensity to KCI and norepinephrine and relaxations to acetylcholine by 14 days of hypertension^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 70052-12-9
Appearance Solid
Molecular Weight 182.17
Formel C₆H₁₂F₂N₂O₂
Color White to light yellow
SMILES

NC(CCCN)(C(F)F)C(O)=O
Synonyms

DFMO; MDL71782; RMI71782; α-difluoromethylornithine
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (23)

All Flow CytometryHistological Imaging/StainingIn Vivo Efficacy StudyRT-PCRBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Nature

Spermine is an endogenous iron chelator that inhibits ferroptosis. [Abstract]

2026 Jul;655(8121):240-250. PMID: 42236947
Immunity

Polyamines regulate adaptive antitumor immunity by functional specialization of regulatory T cells. [Abstract]

2025 Aug 12;58(8):2019-2034.e11. PMID: 40749666

Eflornithine purchased from MedChemExpress. Usage Cited in: Immunity. 2025 Aug 12;58(8):2019-2034.e11. [Abstract]

Csnk2b^Treg−/− and Csnk2b^fl/fl mice were inoculated with B16.F10 cells and then orally administered Eflornithine hydrochloride hydrate (1% w/v) in combination with subcutaneous injection of AMXT 1501 around the tumor. We measured tumor growth and analyzed the phenotype of Treg cells in the tumor microenvironment (TME) using multicolor flow cytometry. The combination therapy had no effect on tumor growth in Csnk2b^Treg−/− mice but significantly inhibited tumor growth in Csnk2b^fl/fl mice.
Nat Commun

Metabolic support protects mucosa from ferroptosis in radiation-induced mucositis. [Abstract]

2025 Dec 8. PMID: 41361241
Nat Commun

Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancer. [Abstract]

2024 Mar 19;15(1):2461. PMID: 38504107
Adv Sci (Weinh)

Efferocytosis-Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer. [Abstract]

2025 Nov 21:e12508. PMID: 41271556

Eflornithine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 21:e12508. [Abstract]

Bar graphs showing the proportion of ALDH+ cells in OVCAR3, OVCAR8, and SKOV3 treated with THP-1-derived Mφ+ACs CM, THP-1-derived Mφ+ACs treated with 1 mM Eflornithine CM, respectively, for 48 h were presented.

Eflornithine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 21:e12508. [Abstract]

Bar graph showing the relative mRNA expression of SOX2, ALDH1A1, and ALDH1A3 in OVCAR3 treated with THP-1 derived Mφ +ACs CM, THP-1 derived Mφ+ACs treated with 1 mM Eflornithine CM separately for 48 h.
J Clin Invest

2026 Jun 11.
Sci Adv

Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8+ T cell cytotoxicity and proliferation. [Abstract]

2023 May 19;9(20):eade0718. PMID: 37205755

Eflornithine purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 May 19;9(20):eade0718. [Abstract]

Percentage of IFN-γ+ and mean fluorescence intensity (MFI) of Ki-67 in CD8⁺ T cells after anti-CD3 antibody stimulation versus anti-CD3 antibody plus rSema4A stimulation with or without Sardomozide Dihydrochloride (10 μM) and Eflornithine hydrochloride hydrate (500 μM).
Clin Cancer Res

Spermidine Secreted by Apoptotic Cells Enhances Chemotherapy Resistance by Modulating β-Catenin Activity in Osteosarcoma. [Abstract]

2025 Nov 20. PMID: 41263700
Phytomedicine

Oleic acid regulates CD4+ T cells differentiation by targeting ODC1-mediated STAT5A phosphorylation in Vogt-Koyanagi-Harada disease. [Abstract]

2025 Jun:141:156660. PMID: 40203473
JACC Basic Transl Sci

Targeting Myocardial Mitochondria-STING-Polyamine Axis Prevents Cardiac Hypertrophy in Chronic Kidney Disease. [Abstract]

2022 Aug 3;7(8):820-840. PMID: 36061341
Cell Rep

Intestinal microbiota affects the progression of colorectal cancer by participating in the host intestinal arginine catabolism. [Abstract]

2025 Feb 28;44(3):115370. PMID: 40022728
Cell Rep

Polyamine metabolism dysregulation contributes to muscle fiber vulnerability in ALS. [Abstract]

2025 Jan 28;44(1):115123. PMID: 39932195
Food Biosci

2023 Oct, 55, 102970.
Commun Biol

Lactobacillus maintains healthy gut mucosa by producing L-Ornithine. [Abstract]

2019 May 8:2:171. PMID: 31098404

Eflornithine purchased from MedChemExpress. Usage Cited in: Commun Biol. 2019 May 8:2:171. [Abstract]

Eflornithine (DFMO) was administered as a 1% solution in drinking distilled H₂O to mice for 14 days. The mean DFMO consumption of mice was ∼1.5 g/kg/d. Immunostaining of IDO1 in the ileum after L-Orn administration in wt mice or after L-Orn inhibitor DFMO administration in human REG3A^tg mice was performed.

Eflornithine purchased from MedChemExpress. Usage Cited in: Commun Biol. 2019 May 8:2:171. [Abstract]

Eflornithine (DFMO) was administered as a 1% solution in drinking distilled H₂O to mice for 14 days. The mean DFMO consumption of mice was ∼1.5 g/kg/d. HPLC/MASS of L-Kyn in the ileum epithelial cells after administration of L-Orn or L-Orn inhibitor DFMO.

Eflornithine purchased from MedChemExpress. Usage Cited in: Commun Biol. 2019 May 8:2:171. [Abstract]

Eflornithine (DFMO) was administered as a 1% solution in drinking distilled H₂O to mice for 14 days. The mean DFMO consumption of mice was ∼1.5 g/kg/d. Flow cytometry of RORγt (+) IL-22(+) cells in the ileum of mice after administering L-Orn or L-Orn inhibitor DFMO.
Cancer Nanotechnol

2023 May 9.
RSC Adv

Spermine modified polymeric micelles with pH-sensitive drug release for targeted and enhanced antitumor therapy. [Abstract]

2019 Apr 9;9(20):11026-11037. PMID: 35520220
Front Oncol

Dual Inhibition of Ornithine Decarboxylase and A1 Adenosine Receptor Efficiently Suppresses Breast Tumor Cells. [Abstract]

2021 Mar 11:11:636373. PMID: 33777791
Oncotargets Ther

Simultaneous Inhibition of Ornithine Decarboxylase 1 and Pyruvate Kinase M2 Exerts Synergistic Effects Against Hepatocellular Carcinoma Cells. [Abstract]

2020 Nov 17;13:11697-11709. PMID: 33244237
J Cardiovasc Transl Res

LACC1 Enhances Polyamine Immunometabolism in Inflammatory Macrophages to Inhibit Atherosclerosis Progression. [Abstract]

2025 Jun;18(3):459-470. PMID: 40293654
Biochem Biophys Res Commun

Alpha-difluoromethylornithine suppresses angiogenesis via the FLI1-CLEC14A-VEGFC pathway in retinal endothelial cells. [Abstract]

2026 Feb 12:800:153251. PMID: 41548484
The University of Texas at San Antonio

2025.
Preprints

2025 May 22.
bioRxiv

2024 Jan 15.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 83.33 mg/mL (457.43 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.4894 mL

27.4469 mL

54.8938 mL

5 mM

1.0979 mL

5.4894 mL

10.9788 mL

10 mM

0.5489 mL

2.7447 mL

5.4894 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Protokoll

Animal Administration^[3]

Mice: The skin area where the hair is removed is then treated with the eflornithine hydrochloride 13.9% cream (∼50 mg per mouse per treatment) using a spatula 2 times a day in an interval of at least 8 h for a maximum period of 36 days^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Burri C, et al. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res. 2003 Jun;90 Supp 1:S49-52. [Content Brief]

[2]. Balfour JA, et al. Topical eflornithine. Am J Clin Dermatol. 2001;2(3):197-201; discussion 202. [Content Brief]

[3]. Kumar A, et al. A method to improve the efficacy of topical eflornithine hydrochloride cream. Drug Deliv. 2016 Jun;23(5):1495-501. [Content Brief]

[4]. Lipke DW, et al. Eflornithine alters changes in vascular responsiveness associated with coarctation hypertension. Clin Exp Hypertens. 1997 Apr;19(3):297-312. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	5.4894 mL	27.4469 mL	54.8938 mL	137.2345 mL
	5 mM	1.0979 mL	5.4894 mL	10.9788 mL	27.4469 mL
	10 mM	0.5489 mL	2.7447 mL	5.4894 mL	13.7234 mL
	15 mM	0.3660 mL	1.8298 mL	3.6596 mL	9.1490 mL
	20 mM	0.2745 mL	1.3723 mL	2.7447 mL	6.8617 mL
	25 mM	0.2196 mL	1.0979 mL	2.1958 mL	5.4894 mL
	30 mM	0.1830 mL	0.9149 mL	1.8298 mL	4.5745 mL
	40 mM	0.1372 mL	0.6862 mL	1.3723 mL	3.4309 mL
	50 mM	0.1098 mL	0.5489 mL	1.0979 mL	2.7447 mL
	60 mM	0.0915 mL	0.4574 mL	0.9149 mL	2.2872 mL
	80 mM	0.0686 mL	0.3431 mL	0.6862 mL	1.7154 mL
	100 mM	0.0549 mL	0.2745 mL	0.5489 mL	1.3723 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Eflornithine

23 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Eflornithine

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

FDA Approved & Pharmacopeial Drug Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Amino Acid Metabolism Compound Library

Non-natural Amino Acid Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Eflornithine

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (23)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Eflornithine

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

FDA Approved & Pharmacopeial Drug Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Amino Acid Metabolism Compound Library

Non-natural Amino Acid Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Eflornithine

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (23)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Eflornithine Related Classifications

HY-B0744 Related Classifications